Emactuzumab

Emactuzumab is a monoclonal antibody developed by SynOx Therapeutics and Hoffmann-La Roche. Its target is CSF1R (the sponsor names CSF-1R). The sponsor states: Emactuzumab is given as five intravenous infusions once every two weeks; a trial exclusion criterion (prior therapy targeting CSF-1 or CSF-1R) indicates it is a CSF-1R-directed antibody used to treat tenosynovial giant cell tumour by disrupting CSF-1/CSF-1R signalling. ClinicalTrials.gov describes the intervention as: Emactuzumab administered once every 2 weeks (q2w). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05417789 (Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT)) and NCT03768063 (A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study), in tenosynovial giant cell tumour. The largest, NCT03768063, plans to enrol 1000 participants with primary completion expected 2028-07-05. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.